Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy.
EuroIntervention. 2018 Feb 20;13(14):1667-1669. doi: 10.4244/EIJ-D-17-00626.
Coronary sinus (CS) Reducer is currently indicated for the treatment of refractory angina in patients unsuitable for coronary revascularization. A 15-30% of non-responders is a constant across literature. Alternative coronary venous drainage systems may be an important factor in determining if patients "respond" to this intervention. We propose a simple method to indirectly assess the presence of these alternative drainage systems and predict responsiveness to Reducer implantation.
We measure the differential pressure between baseline right atrial pressure and CS systolic pressure during balloon occlusion of the CS. In the majority of patients, most of the left coronary artery venous return is drained by the CS. These patients show a high differential pressure due effective interference of the Reducer with coronary venous return. Narrowing of the CS effectively reduces venous return establishing its anti-ischemic effects, with the most expected benefit from Reducer implantation. Patients with developed accessory venous drainage systems will show low differential pressures due to preserved alternative coronary venous outflow. In these patients, Reducer results in an insufficient pressure gradient across the CS and the anti-ischemic effects and benefits might be minimal.
We suggest a simple and effective diagnostic peri-procedural method that may provide additional information in predicting responders to Reducer therapy. We also explore CS hemodynamics in the setting of Reducer implantation, trying to give insights on the pathophysiology and biologic effect of this novel treatment. This may help clinicians to better select patients to undergo implantation, avoiding useless procedures and risks.
目前,冠状窦(CS)减容术被用于治疗不适合进行冠状动脉血运重建的难治性心绞痛患者。文献中报道有 15%-30%的患者对此治疗无反应。冠状静脉的其他引流系统可能是决定患者对该干预措施是否“有反应”的一个重要因素。我们提出了一种简单的方法,可间接评估这些替代引流系统的存在,并预测对减容植入的反应性。
我们在 CS 球囊闭塞期间测量右心房压力与 CS 收缩压之间的压差。在大多数患者中,大部分左冠状动脉静脉回流是由 CS 引流的。这些患者由于 Reducer 有效干扰了冠状静脉回流,因此表现出较高的压差。CS 的狭窄有效地减少了静脉回流,从而建立了其抗缺血作用,从 Reducer 植入中获得最大的益处。已经形成辅助静脉引流系统的患者由于存在替代性冠状动脉静脉流出,因此会显示出较低的压差。在这些患者中,Reducer 会导致 CS 上的压力梯度不足,从而使抗缺血作用和益处最小化。
我们建议一种简单有效的诊断性围手术期方法,该方法可能会提供有关对 Reducer 治疗有反应的患者的更多信息。我们还探讨了 Reducer 植入时 CS 的血液动力学情况,试图深入了解这种新型治疗方法的病理生理学和生物学效应。这可能有助于临床医生更好地选择接受植入的患者,避免不必要的手术和风险。